Zogenix, Inc. (NASDAQ:ZGNX) – Research analysts at Leerink Swann issued their FY2017 earnings per share (EPS) estimates for Zogenix in a note issued to investors on Sunday, according to Zacks Investment Research. Leerink Swann analyst G. Porges expects that the company will earn ($4.17) per share for the year. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Zogenix’s Q4 2017 earnings at ($0.80) EPS, Q1 2018 earnings at ($0.77) EPS, Q2 2018 earnings at ($0.85) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.98) EPS, FY2018 earnings at ($3.09) EPS and FY2019 earnings at ($1.56) EPS.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Tuesday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.17). Zogenix had a negative net margin of 309.76% and a negative return on equity of 81.65%. During the same quarter last year, the firm earned ($0.95) EPS.
A number of other research analysts have also recently weighed in on ZGNX. JMP Securities started coverage on shares of Zogenix in a research report on Monday, November 27th. They set an “outperform” rating and a $56.00 price target on the stock. Mizuho reaffirmed a “buy” rating and set a $51.00 price target on shares of Zogenix in a research report on Thursday, December 7th. BidaskClub raised shares of Zogenix from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Zacks Investment Research raised shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, January 27th. Finally, ValuEngine raised shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Zogenix has a consensus rating of “Buy” and a consensus target price of $46.40.
Shares of Zogenix (ZGNX) remained flat at $$44.50 during mid-day trading on Wednesday. 211,104 shares of the company were exchanged, compared to its average volume of 601,354. The stock has a market capitalization of $1,530.00, a price-to-earnings ratio of -12.63 and a beta of 1.57. Zogenix has a 1-year low of $10.00 and a 1-year high of $45.85.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Stifel Financial Corp acquired a new position in shares of Zogenix during the second quarter worth $175,000. Voya Investment Management LLC lifted its position in shares of Zogenix by 13.5% during the second quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock worth $205,000 after purchasing an additional 1,686 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Zogenix during the third quarter worth $226,000. Sterling Capital Management LLC acquired a new position in shares of Zogenix during the third quarter worth $237,000. Finally, Alliancebernstein L.P. lifted its position in shares of Zogenix by 16.3% during the second quarter. Alliancebernstein L.P. now owns 17,812 shares of the company’s stock worth $258,000 after purchasing an additional 2,500 shares in the last quarter.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.